Abstract 14667: Risk Profiles and Antithrombotic Treatment of Patients With Atrial Fibrillation in China: China Registry of Atrial Fibrillation (CRAF)
Background: Limited data are available on the CHADS2, CHA2DS2-VASc score and management of antithrombotic therapy in atrial fibrillation (AF) patients in China. The objective of this study is to investigate the risk profile and current anticoagulation therapy in Chinese AF patients.
Methods: The China registry of AF (CRAF) is a multicenter, cross-sectional study of patients with atrial fibrillation in mainland China. From July to December2012, enrollment took place in 111 hospitals. Data collected included demographics, medical history, stroke risk (CHADS2 and CHA2DS2-VASc score), antithrombotic treatment and INRs within previous 6 months if the patients had been taking warfarin.
Results: A total of 4,181 patients were recruited and 3551 patients (85.6%) had non-valvular atrial fibrillation (NVAF). The prevalence of ischemic stroke/TIA and systematic embolism was 15.2%.
3773(91.1%) patients received antithrombotic therapy, while most (62.7%) of which received antiplatelet therapy only, 35.5% received warfarin. For patients with valvular atrial fibrillation, 55.5% received Warfarin and 23.8% in those with NVAF.
In 3551 patients with NVAF, mean age was 69.32±11.63 and 56.74% were male. The median CHADS2 score was 2.0. 18.6%, 27.5%, and 54.0% had a score =0, 1 and ≥2, respectively. Median CHA2DS2-VASc score was 3.0 and 79.9% of all the patients had score ≥2.
In NVAF patients with CHADS2 score ≥ 2, only 21.4% received warfarin. The proportions of the patients receiving warfarin decreased as CHADS2 and CHA2DS2-VASc increased (Fig.1A&B).
There were 670(64.8%) patients had INRs records, while only 31.8% of them were reached in the target range of 2.0~3.0.
Conclusions: Warfarin is still underused in patients with NVAF at high risk of stroke. In patients who use warfarin, INR is not regularly monitored and poorly controlled.
- © 2013 by American Heart Association, Inc.